Brief: Alteogen Enters Into A License Agreement With Biogen For Development And Commercialization Of Hybrozyme™-Based Subcutaneous Biologics

Alteogen

25/03/2026 12:30

Alteogen Inc 196170.KQ:

ALTEOGEN ENTERS INTO A LICENSE AGREEMENT WITH BIOGEN FOR DEVELOPMENT AND COMMERCIALIZATION OF HYBROZYME™-BASED SUBCUTANEOUS BIOLOGICS

ALTEOGEN INC - TO RECEIVE $20 MILLION UPFRONT AND $10 MILLION UPON SECOND PRODUCT DEVELOPMENT

ALTEOGEN INC - ELIGIBLE FOR UP TO $549 MILLION IN MILESTONE PAYMENTS FOR TWO PRODUCTS

ALTEOGEN INC - FOLLOWING COMMERCIALIZATION, CO ENTITLED TO RECEIVE ROYALTIES BASED ON NET SALES

ALTEOGEN INC - BIOGEN HOLDS OPTION TO DEVELOP THIRD PRODUCT UNDER AGREEMENT

Source text: ID:nPn1Ns0gKa

Further company coverage: 196170.KQ